RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.


Under RAPS

Posted 01 April 2010

A recent study by the Tufts Center for the Study of Drug Development (CSDD) found that the workload for regulatory professionals at pharmaceutical and biotechnology companies has increased dramatically over the last decade. Based on data from mid-size and large pharmaceutical and biotechnology companies with global drug development operations, the study also found that regulatory functions support, on average, 100 major projects per year, two-thirds of which are in clinical research phases.1

Regulatory Focus newsletters

All the biggest regulatory news and happenings.